Management of hepatitis B virus infection in patients with inflammatory bowel disease under immunosuppressive treatment

Hepatitis B remains a significant global clinical problem,despite the implementation of safe and effective vaccination programs.The prevalence of hepatitis B virus(HBV)in patients with inflammatory bowel disease(IBD)largely follows the regional epidemiologic status.Serological screening with hepatitis B surface antigen(HBsAg),and antibodies to hepatitis B surface(anti-HBs)and core(anti-HBc)proteins is a key element in the management of IBD patients and,ideally,should be performed at IBD diagnosis.Stratification of individual cases should be done according to the serologic profile and the IBD-specific treatment,with particular emphasis in patients receiving immunosuppressive regimens.In patients who have not contracted HBV,vaccination is indicated to accomplish protective immunity.Vaccination in immunosuppressed patients,however,is a challenging issue and several strategies for primary and revaccination have been proposed.The risk of HBV reactivation in patients with IBD should be considered in both HBsAg-positive and HBsAg-negative/anti-HBc-positive patients,when immunosuppressive therapies are administered.HBV reactivation is preventable via the administration of prophylactic nucleot(s)ide analogues and should be the standard approach in HBsAg-positive patients.HBsAg-negative/anti-HBcpositive patients represent a non-homogeneous group and bear a significantly lower risk of HBV reactivation.Biochemical,serological and molecular monitoring is currently the recommended approach for anti-HBc patients.Acute HBV infection is rarely reported in IBD patients.In the present review,we outline the problems associated with HBV infection in patients with IBD and present updated evidence for their management.